Inflammatory B cells defined by TIM-4 in the Alloimmune response

同种免疫反应中 TIM-4 定义的炎症 B 细胞

基本信息

项目摘要

Summary: It is clear that B cells play important Ab-independent roles either promoting or inhibiting immune responses through the opposing activity of regulatory B cells (Bregs) and proinflammatory effector B cells (Beff). This is likely to explain observations that B cell depletion with anti-CD20 can rapidly improve auto- immune diseases, such as RA and MS, without depleting auto-Ab. Yet in other patients, disease is worsened. Moreover, peri-transplant depletion of B cells can markedly increase acute rejection in renal allograft recipients and chronic vasculopathy in heart transplantation. These contradictory results are likely due to the presence of both Bregs and Beff, and not knowing which predominates at a given time, in a given clinical setting, or in a given patient. A similar dichotomy is present in mice, where B cell depletion/deficiency can either inhibit or promote autoimmunity and allograft rejection. We contend that targeting B cells in autoimmune and transplant patients would have far better results if Beff were selectively targeted and Bregs were left intact. Unfortunately, little is known about Bregs, and even less is known about Beff cells. In mice, B cells expressing pro- inflammatory cytokines such as IL-6 and IFNγ play a key role promoting autoimmune responses in EAE and proteoglycan-induced arthritis. Moreover, in response to various infections, B cells exhibit rapid and transient innate-like protective responses through expression of TNFα, IFNγ, IL-2, and IL-17. However, it is unknown whether, or how, any of these responses relate to one another, because no phenotype for such Beff has been established and individual cytokines were examined in isolation. Thus, major aspects of Beff biology, including what regulates their differentiation and cytokine expression, are completely unknown. We have now discovered that TIM-4 identifies Beff that express inflammatory cytokines including IFNγ and IL-17, and accelerate allograft rejection. Eliminating expression of these cytokines by B cells, reverses this proinflammatory role, but can also markedly inhibit the alloimmune response and promote tolerance. Moreover, some cytokines affect the expression of others. Notably, IL-17 is not only a potent effector cytokine, but is essential for Beff to develop an inflammatory rather than regulatory program. Finally, TIM-4 ligation inhibits expression of proinflammatory cytokines. Understanding the role of TIM-4+ Beff in priming the immune response and identifying how this response can be regulated to promote tolerance, are key and unique aspects of this proposal. These results are likely to provide a unifying framework for understanding Beff cells, and will have major impact on the field. In Aim 1 we will determine whether TIM-4+ Beff express a “proinflammatory module” comprised of additional effector molecules and transcriptional regulatory elements, and determine key aspects of its regulation. In Aim 2 we will define key mechanisms by which TIM-4+ Beff promote allograft rejection. In Aim 3 we will determine how TIM-4 signaling regulates expression of the Beff pro-inflammatory module. This work will greatly enhance our understanding of Beff biology and provide therapeutic insights highly relevant to immune tolerance.
摘要:很明显,B细胞在促进或抑制免疫的重要角色中扮演重要的AB独立角色 通过调节B细胞(BREG)和促炎效应B细胞的相反活性的反应 (beff)。这可能解释了观察到的,抗CD20的B细胞部署可以迅速改善自动 免疫疾病,例如RA和MS,而无需耗尽自动aB。然而,在其他患者中,疾病恶化。 此外,B细胞的移植置植物耗竭可显着增加肾脏同种异体移植受体中的急性排斥反应 心脏移植中的慢性血管病。这些矛盾的结果可能是由于存在 Bregs和Beff,并且不知道在给定时间,在给定的临床环境中或在 给予病人。在小鼠中也存在类似的二分法,其中B细胞部署/缺乏可以抑制或 促进自身免疫性和同种异体移植排斥。我们认为,靶向自身免疫和移植中的B细胞 如果将BEFF选择性地靶向并且Bregs保持完整,则患者的结果将会更好。很遗憾, 关于Bregs的知之甚少,对Beff细胞的了解较少。在小鼠中,B细胞表达pro- IL-6和IFNγ等炎性细胞因子促进EAE和EAE自身免疫反应的关键作用 蛋白聚糖诱导的关节炎。此外,为了响应各种感染,B细胞暴露了快速和瞬态 通过TNFα,IFNγ,IL-2和IL-17的表达通过表达的先天样保护反应。但是,这是未知的 这些响应中的任何一个是如何相互关系的,因为没有这种Beff的表型 孤立检查建立和单个细胞因子。这是Beff生物学的主要方面,包括 调节其分化和细胞因子表达的是完全未知的。我们现在发现了 TIM-4标识了表达包括IFNγ和IL-17在内的炎症细胞因子的BEFF,并加速了异形 拒绝。消除B细胞对这些细胞因子的表达,逆转这种促炎作用,但也可以 明显抑制同种免疫反应并促进耐受性。此外,某些细胞因子会影响 他人的表达。值得注意的是,IL-17不仅是潜在效应子细胞因子,而且对于Beff而言, 炎症而不是监管计划。最后,TIM-4连接抑制促炎的表达 细胞因子。了解TIM-4+ BEFF在启动免疫反应并确定这一点的作用 可以调节响应以促进宽容,是该提案的关键和独特方面。这些结果 可能会提供一个统一的框架来理解Beff细胞,并对该领域产生重大影响。 在AIM 1中,我们将确定tim-4+ beff是否表示附加的“促炎模块” 效应子分子和转录调节元件,并确定其调节的关键方面。目标 2我们将定义TIM-4+ BEFF促进同种异体移植排斥的关键机制。在AIM 3中,我们将确定 TIM-4信号传导如何调节BEFF促炎模块的表达。这项工作将大大改善 我们对BEFF生物学的理解,并提供与免疫耐受性高度相关的热见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID M ROTHSTEIN其他文献

DAVID M ROTHSTEIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID M ROTHSTEIN', 18)}}的其他基金

Role of TIM Molecules in Regulatory and Inflammatory B cells in Allo andAutoimmunity
TIM 分子在同种异体和自身免疫中调节性和炎症性 B 细胞中的作用
  • 批准号:
    9751742
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10455066
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Inflammatory B cells defined by TIM-4 in the Alloimmune response
同种免疫反应中 TIM-4 定义的炎症 B 细胞
  • 批准号:
    10214481
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Immunoregulation by TLR-activated TIM-1+ ProB Cells in Transplantation
TLR 激活的 TIM-1 ProB 细胞在移植中的免疫调节
  • 批准号:
    10455069
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Role of TIM Molecules in Regulatory and Inflammatory B cells in Allo andAutoimmunity
TIM 分子在同种异体和自身免疫中调节性和炎症性 B 细胞中的作用
  • 批准号:
    10214475
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10214476
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Role of TIM Molecules in Regulatory and Inflammatory B cells in Allo andAutoimmunity
TIM 分子在同种异体和自身免疫中调节性和炎症性 B 细胞中的作用
  • 批准号:
    10455065
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Immunoregulation by TLR-activated TIM-1+ ProB Cells in Transplantation
TLR 激活的 TIM-1 ProB 细胞在移植中的免疫调节
  • 批准号:
    10214480
  • 财政年份:
    2018
  • 资助金额:
    $ 41.58万
  • 项目类别:
Inflammatory B Cells Defined by TIM-4 in the Alloimmune Response
TIM-4 在同种免疫反应中定义的炎症 B 细胞
  • 批准号:
    9542016
  • 财政年份:
    2017
  • 资助金额:
    $ 41.58万
  • 项目类别:
In Vivo Detection And Mechanisms Of Regulatory B Cell Function In Transplantation
移植中调节性 B 细胞功能的体内检测和机制
  • 批准号:
    9197259
  • 财政年份:
    2015
  • 资助金额:
    $ 41.58万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Climate Change Effects on Pregnancy via a Traditional Food
气候变化通过传统食物对怀孕的影响
  • 批准号:
    10822202
  • 财政年份:
    2024
  • 资助金额:
    $ 41.58万
  • 项目类别:
Leveraging COVID-19 to modernize depression care for VA primary care populations
利用 COVID-19 实现 VA 初级保健人群的抑郁症护理现代化
  • 批准号:
    10636681
  • 财政年份:
    2023
  • 资助金额:
    $ 41.58万
  • 项目类别:
Establishment of a Bat Resource for Infectious Disease Research
建立用于传染病研究的蝙蝠资源
  • 批准号:
    10495114
  • 财政年份:
    2023
  • 资助金额:
    $ 41.58万
  • 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
  • 批准号:
    10456380
  • 财政年份:
    2023
  • 资助金额:
    $ 41.58万
  • 项目类别:
Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
免疫调节配体 B7-1 在神经变性中靶向 p75 神经营养蛋白受体
  • 批准号:
    10660332
  • 财政年份:
    2023
  • 资助金额:
    $ 41.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了